Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
EMA Adds Anktiva to Additional Monitoring List in March 2026
EMA’s March 2026 additional monitoring update added Anktiva, reminding readers how closely new or conditionally authorised products are watched.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
CVMP March 2026 Meeting Highlights Keep Veterinary Safety on the Radar
EMA’s March 2026 CVMP meeting highlights are a reminder that pharmacovigilance and regulatory change remain active in veterinary medicines too.
EMA Pushes ESMP Training as Shortage Reporting Matures
EMA’s new ESMP training and ongoing platform guidance show that shortage reporting is becoming a more structured digital capability across Europe.
MHRA Approves Deuruxolitinib for Severe Alopecia Areata
MHRA has approved deuruxolitinib for adults with severe alopecia areata, while noting the medicine will remain under close safety and effectiveness review.
FDA Requests Removal of Suicidal Ideation Warning From GLP-1 Labels
FDA is asking that suicidal ideation and behavior language be removed from certain GLP-1 RA labels after a review found no increased risk.
FDA Requires Vitamin B6 Deficiency Warning for Carbidopa/Levodopa
FDA is requiring updated labeling for carbidopa/levodopa products to warn about vitamin B6 deficiency and associated seizures, adding a new safety point for Parkinson’s treatment monitoring.
Why Product Management Service and SPOR Literacy Can Strengthen a PV Career
PMS and SPOR may sound like niche data topics, but EMA’s guidance shows they can strengthen credibility in regulated digital and product-governance roles.
Featured Posts
Why Product Management Service and SPOR Literacy Can Strengthen a PV Career
PMS and SPOR may sound like niche data topics, but EMA’s guidance shows they can strengthen credibility in regulated digital and product-governance roles.
FDA’s Action on Xylazine Imports Shows How Safety Oversight Extends Beyond Approved Drugs
FDA’s restrictions on unlawful xylazine imports are a reminder that safety oversight can extend well beyond approved medicines and labeled use.
MHRA’s National Assessment Procedure Update: Why It Matters in 2026
MHRA’s updated national assessment procedure guidance is another reminder that UK regulatory pathways are still evolving and still matter to PV-adjacent teams.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Contact us
Email Us
editor@pvwatchdaily.com